"Neoadjuvant therapy of breast; Molecular profiling"@en . "http://www.isvav.cz/projectDetail.do?rowId=NS10373"^^ . "Neoadjuvant therapy of breast" . . . "2011-08-08+02:00"^^ . "1"^^ . . "1"^^ . "2013-10-31+01:00"^^ . "2"^^ . "\u010Cetnost patologick\u00E9 kompletn\u00ED odpov\u011Bdi byla statisticky v\u00FDznamn\u011B ni\u017E\u0161\u00ED ve skupin\u011B HR+/HER2- (p=0,03) s vy\u0161\u0161\u00ED aktivitou topoisomer\u00E1zy IIa a NADPH oxidoredukt\u00E1zy oproti HR-/HER2- a HR+/HER2+ nemocn\u00FDm."@cs . "Neoadjuvantn\u00ED l\u00E9\u010Dba karcinomu prsu" . . "2"^^ . . "Neoadjuvant chemotherapy has been considered the standard care in locally advanced breast cancer. About 20% of the patients do not benefit from this clinical treatment, and predictive factors of response were not defined yet. This study was designed to evaluate the importance of biological markers to predict response and prognosis in stage II and III breast cancer patients treated with taxane and anthracycline combination as neoadjuvant setting. To fulfill this goal, the expression of tumor cell cycle/proliferation regulators (ER, PR, BCL-2, HER-2, CD40, NQO-1, p21 and EGFR), cytostatic agent\u2019s targets (MDR1, pregnane X receptor, microtubule-associated protein tau, and Topoisomerase IIa), and regulatory chemokines (e.g. RANTES, IL-8, MCP-1) will be evaluated before initiation, during the course, and after finishing of neoadjuvant therapy at protein and mRNA level. Data will be compared with clinical and biochemical examinations to allow potential prediction of pathologic complete response (pCR)."@en . . . . "NS10373" . . . . . "Neoadjuvantn\u00ED chemoterapie je pova\u017Eov\u00E1na za standardn\u00ED p\u00E9\u010Di u lok\u00E1ln\u00EDho karcinomu prsu v pokro\u010Dil\u00E9m st\u00E1diu. Nicm\u00E9n\u011B, asi u 20% pacientek nen\u00ED tato klinick\u00E1 l\u00E9\u010Dba \u00FAsp\u011B\u0161n\u00E1 a prediktivn\u00ED faktory odpov\u011Bdi na l\u00E9\u010Dbu u nich nebyly dosud definov\u00E1ny. Tato studie je navr\u017Eena za \u00FA\u010Delem zhodnocen\u00ED v\u00FDznamu biologick\u00FDch marker\u016F v odhadnut\u00ED odezvy a progn\u00F3zy u pacientek ve II. a III. stupni karcinomu prsu, l\u00E9\u010Den\u00FDch kombinac\u00ED taxanu a anthracyclinu. Pro spln\u011Bn\u00ED tohoto c\u00EDle budou hodnoceny exprese regul\u00E1tor\u016F proliferace n\u00E1dorov\u00FDch bun\u011Bk (ER, PR, BCL-2, HER-2, CD40, NQO-1, p21 a EGFR), c\u00EDlov\u00FDch struktur cytostatik (MDR1, pregnanov\u00FD X receptor, microtubule-associated protein tau a Topoisomer\u00E1za IIa) a regula\u010Dn\u00EDch chemokin\u016F (nap\u0159. RANTES, IL-8, MCP-1) p\u0159ed zah\u00E1jen\u00EDm, v pr\u016Fb\u011Bhu a po ukon\u010Den\u00ED neoadjuvantn\u00ED terapie nejen na \u00FArovni proteinu, ale tak\u00E9 mRNA. Molekul\u00E1rn\u00ED hodnoty budou porovn\u00E1ny s v\u00FDsledky klinick\u00FDch a biochemick\u00FDch vy\u0161et\u0159en\u00ED, co\u017E umo\u017En\u00ED potenci\u00E1ln\u00ED p\u0159edpov\u011B\u010F patologick\u00E9 kompletn\u00ED odezvy (pCR)." . "2011-12-31+01:00"^^ . "0"^^ . . . . . "2009-01-01+01:00"^^ . "Neoadjuvant chemoterapy in brest carcinoma"@en . "Patological complete response rate was significantly lower in HR+/HER2- tumors (p=0,03) with increased expression of Topoisomerase IIa and NADPH oxidoreductase comparing to HR-/HER2- and HR+/HER2+ tumors."@en . . .